Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

China

Clinical Trials Are Increasingly Going Global—With China a Main Beneficiary

AstraZeneca’s $15 billion pledge to its China operations highlights the country’s advantages. But other regions are also hoping to host more clinical studies.

February 2, 2026

8 min read

Annalee Armstrong

Creative concept of Left and right brain illustration with colorful on right side isolated on dark background

Psychedelics

Psychedelics Space at a ‘Tipping Point’ as Compass, Definium Gear Up To File for Approval

With Lykos’ regulatory failure now squarely in the rearview mirror, Compass Pathways and Definium are leading what one analyst suspects will be “a very big year for psychedelics.”

February 2, 2026

7 min read

Heather McKenzie

A scientist with pill bottles in front of FDA headquarters

Regulatory

FDA Action Alert: Sanofi/Regeneron, Merck, REGENXBIO and More

In what is shaping up to be a back-loaded month, the FDA is set to release a slew of regulatory decisions in February, including two that would expand the labels of blockbuster drugs.

February 2, 2026

7 min read

Tristan Manalac

UFO looking like White house abducting a man. Conspiracy theory, paranoia afunny concept.Vector illustration.

Rare diseases

Despite Wide Support for Rare Disease, Voucher Program Caught Up in Senate’s ICE Fight

The Senate failed to pass a massive spending bill on Thursday—which includes the rare pediatric PRV program but also funding for the Immigration and Customs Enforcement’s large-scale crackdown in Minnesota and other states.

January 30, 2026

3 min read

Annalee Armstrong

Cancer

FDA’s Multiple Myeloma Guidance Highlights Decade of Success

New draft guidance from the FDA on multiple myeloma endpoints reflects the new technology available to assess disease and how patient journeys have changed with better treatments.

January 30, 2026

4 min read

Dan Samorodnitsky

President Donald Trump signs S.1852, The GENIUS Act, Friday, July 18, 2025, in the East Room of the White House. (Official White House Photo by Daniel Torok)

Drug pricing

TrumpRx Delayed Amid Potential Anti-Kickback Concerns

In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.

January 30, 2026

2 min read

Tristan Manalac

Deals

Moderna Teams With Recordati on Rare Disease mRNA Therapy for up to $160M

Moderna will continue to lead clinical development and manufacturing of the asset, while Recordati will handle commercialization of mRNA-3927, which is under development for the rare metabolic disorder propionic acidemia.

January 30, 2026

1 min read

Annalee Armstrong

Obesity

AstraZeneca’s China Trip Yields CSPC Obesity Deal Worth $1.2B Upfront

The pact, which could see AstraZeneca ultimately put out $18.5 billion in milestones and sales-based payments, is centered on SYH2082, a long-acting dual agonist of the GLP-1 and GIP receptors.

January 30, 2026

2 min read

Tristan Manalac